Table 3 Radiographic progression greater than the smallest detectable change (SDC) after 3 years and IFX discontinuation 2 years after the start of MTX+IFX in the initial and delayed MTX+IFX groups, adjusted for propensity score

	Initial IFX	Delayed IFX	Odds ratio (95% CI)	p Value
Patients with progression SHS>SDC, %	26	50	0.47 (0.24 to 0.95)	0.034
Patients who discontinued IFX due to a sustained DAS ⩽2.4, %	56	29	2.56 (1.27 to 5.16)	0.008

DAS, disease activity score; IFX, infliximab; SDC, smallest detectable change; SHS, modified Sharp/van der Heijde Score.